NeoGenomics is proud to present new scientific insights at the AACR Annual Meeting 2026, and we'd love for you to join our poster sessions. This year, our research highlights advancements in tumor microenvironmental profiling, AI-enabled histopathology, and multi-omics capabilities. 🔗 If you're attending, reach out to us here to book a meeting: https://lnkd.in/gvPrzsUy
NeoGenomics Laboratories
Hospitals and Health Care
Fort Myers, Florida 64,771 followers
One Lab. Vital Answers.
About us
Our mission: We save lives by improving patient care. Our vision: We are becoming the world's leading provider of comprehensive cancer testing, data and solutions through uncompromising quality, exceptional customer experience, and innovative products and services.
- Website
-
http://www.neogenomics.com
External link for NeoGenomics Laboratories
- Industry
- Hospitals and Health Care
- Company size
- 1,001-5,000 employees
- Headquarters
- Fort Myers, Florida
- Type
- Public Company
- Founded
- 2002
- Specialties
- Cytogenetics, Flow Cytometry, Fluorescence In Situ Hybridization (FISH), Molecular Genetics, Immunohistochemistry, Pharma Research Services, Molecular Oncology & Pathology, and Next-Gen Sequencing (NGS)
Locations
-
Primary
Get directions
9490 NeoGenomics Way
Fort Myers, Florida 33912, US
Employees at NeoGenomics Laboratories
Updates
-
Join NeoGenomics at NextGen Omics Spatial & Data US 2026 for a special presentation: Mapping Immunotherapy Resistance: Unlocking Spatial Biology Insights Across the Tumor Microenvironment. Bookmark these details: 🗓️ Wednesday, April 1st 9:40 AM EST 📍 NextGen Omics & Spatial Biology US 2026 We’ll share how spatial biology enables high resolution mapping of immunotherapy resistance mechanisms, supporting optimized enabling response assessment. See you there!
-
-
#ICYMI, we announced the launch of PD-L1 22c3 FDA for Ovarian Carcinoma (🔗 https://lnkd.in/g4S3e8f5), to help uncover targeted therapy options for patients with recurrent ovarian carcinoma, particularly those with platinum-resistant or platinum-refractory disease, for whom treatment options may be limited.
-
-
Discover how PanTracer Pro supports confident decisions: https://lnkd.in/gcekbhYm. With one order, you get comprehensive genomic profiling plus IHC and HRD testing based on tumor type and clinical context.
-
🎯 Target the right patients with RaDaR ST for Pharma Partners: https://bit.ly/4bMpkTU. Use RaDaR® ST to stratify and enrich trial populations, identifying ctDNA-positive individuals most likely to benefit from investigational therapies.
-
-
New white paper! From Data to Decision: Biomarkers Driving Precision Medicine: https://lnkd.in/gjvKi4X6 Gastric cancer remains the 4th leading cause of cancer-related death worldwide, but biomarker-driven therapies are changing the game. HER2, PD-L1, MSI/dMMR, CLDN18.2, and FGFR2b are transforming treatment strategies—offering hope for improved survival and reduced toxicity. #Oncology #PrecisionMedicine #Biomarkers #GastricCancer
-
-
That’s a wrap on #USCAP2026! If you didn’t make it by our booth, we’d still love to connect. Reach out (https://lnkd.in/gFG8j35K) to learn more about our: • Comprehensive solid tumor and heme solutions • PanTracer™ portfolio • Tech-only services • Neo Comprehensive® panels and Compass® solutions • Client Services support
-
-
We're having an incredible time at #USCAP2026! Thank you to everyone who has stopped by booth #639 so far. Our team is energized by the conversations, collaboration, and shared commitment to improving patient care. Stop by if you haven’t yet, we’re at booth #639! #Pathology #OncologyDiagnostics #Oncology
-
-
RaDaR® ST provides clear, actionable answers: https://lnkd.in/g-WMkPMy #NeoGenomics #RaDaRST #PrecisionOncology #MRD